News

The Manila Times18h

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the Eur…

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in ...

Novo Nordisk A/S: Novo Nordisk to present Wegovy and Ozempic data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...